Home Cart Sign in  
Chemical Structure| 292605-14-2 Chemical Structure| 292605-14-2

Structure of SB-3CT
CAS No.: 292605-14-2

Chemical Structure| 292605-14-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SB-3CT is a potent and competitive inhibitor of matrix metalloproteinases MMP-2 and MMP-9, with Ki values of 13.9 and 600 nM, respectively. SB-3CT is highly selective for gelatinases and shows blood-brain barrier permeability, neuroprotective effects, and anticancer activity.

Synonyms: Matrix Metalloproteinase-2/9 Inhibitor IV; MMP-2/MMP-9 Inhibitor IV

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SB-3CT

CAS No. :292605-14-2
Formula : C15H14O3S2
M.W : 306.40
SMILES Code : O=S(CC1SC1)(C2=CC=C(OC3=CC=CC=C3)C=C2)=O
Synonyms :
Matrix Metalloproteinase-2/9 Inhibitor IV; MMP-2/MMP-9 Inhibitor IV
MDL No. :MFCD09836266
InChI Key :LSONWRHLFZYHIN-UHFFFAOYSA-N
Pubchem ID :9883002

Safety of SB-3CT

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H319
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • MMP

    MMP-2, Ki:13.9 nM

    MMP-9, Ki:600 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
C6 cells 30 μM Inhibition of MMP-2/9 can alleviate Pb-induced down-regulation of ZO-1 and occludin. PMC5715519
CD8+ T cells 10 mM 6 h To assess the effect of SB-3CT on T cell proliferation and cytokine production. PMC3095987
Human wild type (WT) podocytes and transgenic podocytes 14 mM 48 hours After MMP-2 inhibition, podocyte apoptosis was attenuated, but NOX4 expression remained almost the same. PMC10496016

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice embolic focal cerebral ischemia model Intraperitoneal injection 25 mg/kg 2 and 4 hours post-ischemia, repeated for seven days SB-3CT treatment reduced infarct volume and ameliorated neurobehavioral outcomes. PMC3500265
Mice tMCAO Intraperitoneal injection 10 mg/kg 3 consecutive days to specifically inhibit MMP-9-driven pathways in vivo PMC5474960
Mice CC10-OVA mice Intratracheal 10 µM 7 days post-administration To evaluate the effects of SB-3CT on T cell accumulation and lung injury. PMC3095987
Mice Col4a3 C1615Y transgenic mice Intraperitoneal injection 50 mg/kg 6 days After MMP-2 inhibition, podocyte apoptosis was attenuated, but NOX4 expression remained almost the same. PMC10496016

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.26mL

0.65mL

0.33mL

16.32mL

3.26mL

1.63mL

32.64mL

6.53mL

3.26mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories